Skip Navigation LinksHome > February 15, 2002 - Volume 16 - Issue 3 > The extent of HIV-1-related immunodeficiency and age predict...
Clinical Science

The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy

Kaufmann, Gilbert R.a,e; Bloch, Markb; Finlayson, Robertc; Zaunders, Johnd; Smith, Dona; Cooper, David A.a,d

Free Access
Article Outline
Collapse Box

Author Information

From the aNational Centre in HIV Epidemiology and Clinical Research, Sydney NSW, 2010, Australia; bHoldsworth House General Practice, Sydney, NSW 2010, Australia; cTaylor Square Private Clinic, Sydney, NSW 2010, Australia; dCentre for Immunology, St Vincent's Hospital, Sydney NSW 2010, Australia; and eOutpatients Department, University Hospital, CH-4031 Basel, Switzerland.

Correspondence to: Dr Mark Bloch, Holdsworth House General Practice, 32A Oxford Street, Darlinghurst, NSW 2010, Sydney, Australia. Tel. +61 2 9331 7228; fax. +61 2 9360 9232; e-mail:

Received: 2 February 2001;

revised: 27 July 2001; accepted: 6 September 2001.

Sponsorship: The National Centre in HIV Epidemiology and Clinical Research is supported by the Australian National Council on AIDS and Related Diseases (ANCARD).

Collapse Box


Objective: To study the long-term immunological recovery in HIV-1-infected individuals receiving potent antiretroviral therapy (ART).

Design: Prospective, observational study.

Methods: Plasma HIV-1 RNA, CD4 and CD8 T lymphocyte counts were determined at 3–6 monthly intervals in 95 HIV-1-infected subjects receiving ART who suppressed plasma HIV-1 RNA to levels below 400 copies/ml during a median observation period of 45 months.

Results: The median CD4 cell count rose from 325 to 624 cells/μl at 48 months, increasing by 22.6 cells/μl per month in the first 3 months, 8.1 cells/μl per month from months 3 to 12, 6.8 cells/μl per month in the second year, 3.3 cells/μl per month in the third, and 1.7 cells/μl per month in the fourth year. At 48 months, 98% of subjects reached CD4 cell counts > 200 cells/μl, 86% > 350 cells/μl, and 74% > 500 cells/μl. A higher nadir CD4 cell count and younger age were independently associated with greater increases in CD4 cell counts, and higher absolute CD4 cell counts at 48 months. Poor immunological responders who did not reach 500 CD4 lymphocytes/μl at 48 months showed lower nadir and baseline CD4 cell counts than good responders (99 versus 300 cells/μl and 160 versus 373 cells/μl, respectively).

Conclusion: The recovery of CD4 T lymphocytes occurs mainly in the first 2 years after the initiation of ART, and is associated with age and the pre-existing degree of HIV-1-related immunodeficiency, suggesting that the long-term exposure to HIV-1 infection has caused damage to the immune system that is difficult to correct.

Back to Top | Article Outline


Potent antiretroviral therapy (ART) efficiently inhibits viral replication, resulting typically in a biphasic decline in plasma HIV-1 RNA [1]. The degree of viral load reduction is inversely associated with the short and medium-term increase in CD4 cell count [2,3], allowing for a slow but gradual quantitative and qualitative recovery of the immune system [4,5].

The CD4 T lymphocyte response to ART is highly variable, which has resulted in early reports of discordant virological and immunological responses [3]. The reasons for the high variability of T cell responses have been insufficiently studied and still remain unclear. It is conceivable that immunological as well as virological factors may be involved. In treatment-naive individuals, a syncytium-inducing T cell tropic viral strain leads to a more rapid decline of CD4 T lymphocytes than a macrophage-tropic strain [6]. As viral replication is not completely suppressed by ART [7,8], a highly cytopathic viral strain may similarly impede the recovery of CD4 T lymphocytes in individuals receiving ART [9]. A second potential factor determining the immunological recovery may be the thymus. Young children with more functional thymus tissue show a more rapid reconstitution of the immune system than older children or adults [10]. Third, the degree of HIV-1-related immunological damage may affect immune restoration. Individuals with advanced HIV-1 infection have progressively lost naive CD4 T lymphocytes [11]. It has been suggested that the number of naive cells predicts the subsequent level of CD4 T lymphocytes that can be reached by ART [12].

In numerous studies [12–16], only a partial normalization of HIV-1-associated immunological alterations has been reported. However, the short follow-up of these investigations does not allow a definitive conclusion about the potentially achievable level of immunological recovery. In this study, we analysed the long-term dynamics of CD4 and CD8 T lymphocytes over 4 years in an observational cohort of HIV-1-infected subjects who commenced ART. Inclusion criteria were based on the aim to evaluate the maximum level of immune reconstitution that can be reached by ART. Therefore, only those individuals were considered who showed a long-term undetectable viral load on ART. In this selected cohort, the characteristics of good and poor immunological responders, as well as baseline parameters that may serve as predictors of the CD4 T cell response to ART, were studied.

Back to Top | Article Outline


Patient population

Subjects were recruited from two primary care practices (Holdsworth House General Practice and Taylor Square Private Clinic, Sydney, Australia). Individuals were eligible if they: (i) commenced ART between January 1996 and December 1997; (ii) reduced plasma HIV-1 RNA to undetectable levels (< 400 copies/ml); and (iii) maintained undetectable plasma HIV-1-RNA values during the observation period. Changes of ART were allowed in the case of adverse events or as requested by patients, as long as the plasma HIV-1 viral load remained below the threshold of detection.

A total of 210 individuals presented with good initial virological responses to ART, suppressing HIV-1 RNA to undetectable levels. However, 115 of these subjects were excluded from analysis, because they either showed a subsequent viral load rebound as a result of the discontinuation of ART or virological failure of the drug regimen, had been pre-treated with a protease inhibitor (PI), or had missing baseline plasma HIV-1-RNA data.

The final analysis was based on data from 95 subjects, who were followed for a median observation period of 45 months. Study participants had a mean age of 40 ± 8 years and 100% were men because of the large predominance of the male homosexual HIV risk group in Sydney (see Table 1). Half of the subjects were treatment naive and half had been pre-treated with nucleoside analogues. Twenty-eight subjects (30%) received indinavir, 27 (29%) saquinavir (hard-gel), and 21 (22%) a combination of ritonavir and saquinavir. A small number of individuals were treated with ritonavir (n = 2), a combination of nelfinavir and saquinavir (n = 1), nevirapine (n = 8) or a combination of a non-nucleoside reverse transcriptase inhibitor (NNRTI) and a PI (n = 4). In addition, four individuals were treated with double nucleoside analogue combinations. The reverse transcriptase inhibitor regimen mainly consisted of stavudine and lamivudine (55%), zidovudine and lamivudine (29%), or stavudine and didanosine (6%). During the observation period, 45 subjects (47%) changed the PI or the NNRTI. Twenty-three individuals (24%) discontinued the PI and received an NNRTI. The reverse transcriptase inhibitor regimen was changed in 61 individuals (64%) because of adverse events.

Table 1
Table 1
Image Tools
Back to Top | Article Outline
Laboratory methods

After whole-blood lysis (FACSlysing Solution, Becton-Dickinson, San Jose, CA, USA), T lymphocyte counts were determined by three-colour flow cytometry using CD45-peridin chlorophyll protein versus side-scatter gating, CD3-FITC, CD4-phycoerythrin and CD8-phycoerythrin monoclonal antibodies (Becton-Dickinson, San Jose, CA, USA). The analysis was performed on an EPICS XL flow cytometer (Coulter Electronics) in accordance with Centers for Disease Control and Prevention (CDC) guidelines.

Plasma HIV-1 RNA was measured using a quantitative reverse transcriptase–polymerase chain reaction using the HIV Monitor test version 1.5 with a lower limit of detection of 400 copies/ml (Roche Molecular Systems, Branchburg, NJ, USA).

Back to Top | Article Outline
Statistical analysis

All results are presented as medians and interquartile ranges, except for age, which is shown as mean ± standard deviation. T cell dynamics were analysed by calculating 3–6 monthly changes of CD4 and CD8 cell counts in the first year of ART and yearly changes thereafter. To allow for irregular visits, missing laboratory values were interpolated using the mean of the two adjacent measurements.

Three major immunological endpoints were analysed, including (i) the absolute CD4 cell count at 48 months (last value after 3 years of ART carried forward); (ii) the increase in CD4 cell count during the observation period and (iii) the proportion of individuals with a CD4 count above 200 cells/μl (threshold for opportunistic infections), above 350 cells/μl (threshold for the initiation of ART [17]), and above 500 cells/μl (lower limit of the normal range). In addition, the proportion of patients who reached normal CD8 cell counts (< 1000 cells/μl) was evaluated. The percentages of T lymphocytes were not analysed, because clinical decisions are usually based on absolute T cell counts.

The relationship between baseline parameters and immunological endpoints was evaluated using either an analysis of variance of ranked data or a logistic regression analysis. A Spearman's rank correlation test was used to evaluate the relationship between T cell changes at different time intervals. Paired baseline and follow-up samples were analysed using a Wilcoxon signed rank test. A two-sided P value less than 0.05 was considered statistically significant. Statistical tests were performed using SPSS version 8.0 (SPSS Inc., Chicago, IL, USA).

Back to Top | Article Outline


In 60% of subjects, the plasma HIV-1-RNA level declined within 3 months from a median of 4.7 log10 copies/ml to a level below the threshold of detection (< 400 copies/ml), 24% reached an undetectable viral load after 3 and 6 months, and 16% reached an undetectable viral load after 6 months. The median CD4 cell count increased from 325 cells/μl at baseline to 624 cells/μl at 48 months (Fig. 1a). A maximum CD4 cell count of 780 cells/μl was attained at 37 months (interquartile range 26–42). The greatest increase in CD4 cell count was observed in the first 3 months (22.6 cells/μl per month). Thereafter, it became gradually smaller, reaching 8.6 cells/μl per month between months 3 and 12, 6.8 cells/μl per month in the second year, 3.3 cells/μl per month in the third, and 1.7 cells/μl per month in the fourth year (Fig. 2a). See Table 1 for baseline characteristics of all subjects.

Fig. 1
Fig. 1
Image Tools
Fig. 2
Fig. 2
Image Tools

The proportion of subjects who reached normal CD4 cell counts (> 500 cells/μl) increased from 17% at baseline to 71–75% at 36–48 months (Fig. 3), whereas the percentage of individuals who reached CD4 cell counts above 350 cells/μl and above 200 cells/μl increased from 43 to 88–91% and from 76 to 94–98%, respectively.

Fig. 3
Fig. 3
Image Tools

In contrast, CD8 cell counts did not show significant changes over time, only slightly declining from 1105 cells/μl at baseline to 1079 cells/μl at 48 months (P = 0.41;Fig. 1a). Median changes in CD8 T lymphocytes in the first, second and third year were −3.7 cells/μl per month, −1.9 cells/μl per month and 3.8 cells/μl per month, respectively (Fig. 2b). In the fourth year, an increase in CD8 cell count of 6.9 cells/μl per month was observed. At 48 months, the CD8 cell count reached the normal range (< 1000 cells/μl) in 36 individuals (44%), but only 23 subjects (28%) showed a normalization of both CD4 and CD8 cell counts. The CD4 to CD8 cell ratio increased from 0.26 at baseline to 0.59 at 48 months, following a similar time course as CD4 T lymphocytes (Fig. 1b).

Twenty-two individuals (26%) met the definition of poor immunological responders, and did not reach a CD4 cell count greater than 500 cell/μl at 48 months. Interestingly, 50% of these subjects intermittently exhibited a CD4 cell count above 500 cells/μl, but could not maintain CD4 cell counts in this range.

Thirty-six subjects (43%) showed a substantial CD4 cell decline of more than 20% from the maximum attained CD4 cell count. In 19 individuals (23%) CD4 cell counts declined by more than 30%, despite suppressing viral load below 400 copies/ml.

Back to Top | Article Outline
Relationship between baseline parameters and the CD4 T cell response

Younger individuals showed greater increases in CD4 cell count than older subjects (P = 0.002;Table 2). In addition, a higher nadir CD4 cell count was significantly associated with a greater increase in CD4 T lymphocytes (P = 0.004).

Table 2
Table 2
Image Tools

Higher CD4 cell counts at 48 months were associated with higher baseline CD4 cell counts (P < 0.001), higher nadir CD4 cell counts (P < 0.001), a less advanced CDC stage (P = 0.001) and younger age (P = 0.002). In a multivariate model, a higher nadir CD4 cell count (P < 0.001) and younger age (P = 0.006) independently predicted higher CD4 cell counts at 48 months (Table 3).

Table 3
Table 3
Image Tools

Six out of 18 subjects (33%) with fewer than 200 CD4 cells/μl at baseline attained a CD4 cell count above 500 CD4 cells/μl at 48 months, whereas 19 out of 27 individuals (70%) with CD4 cell counts between 200 and 350 cells/μl, and all subjects (100%) with more than 350 cells/μl achieved a normal CD4 cell count (> 500 cells/μl;P < 0.001). On the basis of these results, the longitudinal CD4 and CD8 cell count as well as the CD4 to CD8 cell ratio were analysed after the stratification of individuals into three categories of baseline CD4 cell count. This analysis revealed that CD4 T lymphocytes and the CD4 to CD8 cell ratio in the three subgroups followed parallel time courses. In contrast, the CD8 cell count did not show such a pattern (Fig. 4). Consequently, the monthly CD4 T cell changes were similar among the three baseline CD4 cell strata (Fig. 2).

Fig. 4
Fig. 4
Image Tools
Back to Top | Article Outline
Risk factors for a poor immunological response

Nadir and baseline CD4 cell counts were significantly lower in poor immunological responders than in individuals who reached the normal range for CD4 T lymphocytes at 48 months (99 versus 160 cells/μl for nadir CD4 cell count; 160 versus 373 cells/μl for baseline CD4 cell count;P < 0.0001 and P = 0.0001, respectively). Moreover, a trend was observed that individuals with poor immunological responses were older (42 versus 37 years;P = 0.08) and were in a more advanced CDC category (P = 0.08). In contrast, baseline CD8 cell counts, plasma HIV-1-RNA levels and the duration of HIV-1 infection were similar in poor and good responders. In a multivariate logistic regression analysis, the relative risk of a poor immunologial response increased 3.2 times per 100 cells decline in the nadir CD4 cell count, whereas the baseline CD4 cell count did not represent an independent predictor as a result of its significant relationship with the nadir CD4 cell count (r = 0.67;P < 0.001;Table 4).

Table 4
Table 4
Image Tools
Back to Top | Article Outline
Factors associated with the decline in CD4 cell count

Subjects who experienced substantial CD4 cell declines of 20–30% from the maximum attained CD4 cell count showed no distinct characteristics compared with individuals who maintained stable CD4 cell counts (data not shown). In particular, no relationship was observed between changes in ART and a decline in CD4 T lymphocytes. Moreover, subjects with a significant decline (> 20%) in CD4 cell count were found with a similar frequency in the group on NNRTI and in the group on PI (40 versus 49%;P = 0.51).

Back to Top | Article Outline
Relationship between changes in CD4 T lymphocytes in different time intervals

Early CD4 cell count increases during the first 3 and 6 months of ART were significantly associated with the total increase in CD4 T lymphocytes over 48 months (r = 0.52, P < 0.001 and r = 0.55, P < 0.001, respectively). However, early changes in CD4 T lymphocytes were not associated with increases in CD4 cell counts in the second, third and fourth year. Interestingly, changes in CD4 cell count in the second year were inversely correlated with CD4 cell count changes in the third year of ART (r = −0.41, P < 0.001). Similarly, CD4 cell count changes in the third year were inversely correlated with CD4 cell count changes in the fourth year (r = −0.65;P < 0.001).

Back to Top | Article Outline
Influence of antiretroviral therapy on T cell responses

The subgroup of subjects treated continuously with PI (n = 42) and individuals who received NNRTI or were switched from a PI to an NNRTI (n = 53) showed similar baseline CD4 cell counts (323 versus 344 cells/μl;P = 0.56) and subsequent increases in CD4 T lymphocytes during the observation period (313 versus 303 cells/μl;P = 0.38). Moreover, the frequency of poor immunological responders was not significantly different in both groups (20 versus 32%;P = 0.31) and T cell dynamics were similar (data not shown).

Back to Top | Article Outline


The level of immune competence that can be reached in HIV-1-infected individuals receiving ART is of major clinical significance. It is important to detect early those subjects who are likely to belong to the group of poor immunological responders, and have a lengthy exposure to the risk of opportunistic infections. We hypothesized that certain baseline parameters may be associated with the degree of immunological recovery to ART and allow the early detection of these individuals. Such parameters may include: baseline or nadir CD4 cell counts, which reflect the degree of HIV-1-related immunodeficiency; age, which is inversely correlated with thymic function; and baseline viral load, which may serve as a marker of viral fitness.

At 4 years, more than 70% of treated individuals reached the normal range of CD4 T lymphocytes (> 500 cells/μl). Moreover, CD4 cell counts increased in almost all of these individuals to levels above 200 cells/μl, providing protection against major opportunistic infections [18]. HIV-1-related immunodeficiency, as reflected in the baseline or nadir CD4 cell count, was strongly associated with the recovery of CD4 T lymphocytes. A minority of individuals with fewer than 200 CD4 T lymphocytes/μl at baseline reached the normal range of CD4 T lymphocytes after 4 years of ART, whereas a larger proportion of individuals with baseline CD4 cell counts of between 200 and 350/μl, and all subjects with more than 350 CD4 T lymphocytes/μl achieved this goal. This finding supports the concept that the immunological damage caused by HIV-1 over time appears to determine the degree of recovery of CD4 T lymphocytes.

CD4 T lymphocyte dynamics followed three major phases. Consistent with previous reports, a rapid early increase in the CD4 cell count was observed in the first 3 months [4,5,19]. This early phase was followed by a second slower phase, which was characterized by an almost linear increase in the CD4 cell count in the first 2 years. In the third year, the CD4 cell count approached a plateau level, with only minor subsequent changes. Even individuals who commenced ART with low CD4 cell counts showed this pattern of CD4 T lymphocyte dynamics. The largest effect of ART on the recovery of the immune system therefore appears to occur in the first 2 years.

Interestingly, only 28% had a combination of normal CD4 and CD8 cell counts, because most individuals maintained high CD8 cell counts. Persistently elevated CD8 cell counts probably indicate ongoing viral activity and antigen-driven expansion of CD8 T lymphocytes [8]. Residual viral activity may partly explain the large individual variability in the recovery of CD4 T lymphocytes.

Twenty-five per cent of individuals belonged to the category of poor or moderate immunological responders. CD4 cell counts increased very slowly in these individuals, and did not reach the normal range (500 cells/μl) at 48 months. Whether poor responders will eventually reach a CD4 cell count of 500 cell/μl after a longer observation period cannot conclusively be answered in this study, but it may take at least 6–8 years in some individuals to reach this level of CD4 cell count. The risk of a poor immunological response increased with a lower baseline CD4 cell count and a lower nadir CD4 cell count. Moreover, there was a trend that older patients were more likely to experience poorer immunological responses. It is conceivable that poor immunological responders are individuals who have experienced more severe HIV-1-related damage to the immune system. The relationship between age and the immunological response supports the concept of an age-related decline in thymic function and probably other regenerative mechanisms, such as the peripheral expansion of CD4 T lymphocytes [10,20, 21].

The CD4 cell count began to decline substantially in a large proportion of subjects after the maximum CD4 cell count had been reached. The reason for this finding remains unclear. None of the evaluated baseline parameters was associated with the decline in CD4 cell count. In particular, the current drug regimen or changes in ART did not seem to be associated with a decline in CD4 cell count. As the subgroups receiving distinct ART regimens were small and CD4 cell count changes were observed very late at 2–3 years, this finding requires further investigation in a larger study with a longer follow-up.

Interestingly, early increases in CD4 T lymphocytes in the first 6 months were highly associated with the total change in CD4 T lymphocyte number over 48 months, but not with CD4 T cell changes in the second, third or fourth year. The relationship between the early and total increase in CD4 cell count indicates that early changes in CD4 cell counts contribute substantially to the overall recovery of CD4 T lymphocytes. The lack of a relationship between early and late CD4 cell increases suggests that distinct mechanisms may be responsible for the recovery of CD4 T lymphocytes in different phases of immune reconstitution. There is growing evidence that the mechanism responsible for the initial increase in CD4 cell count is mainly the entrapment of CD4 T lymphocytes in the lymphoid tissue, which are released upon the initiation of ART [22]. In contrast, the late phase increase may be the result of the peripheral expansion of circulating memory cells [23].

Back to Top | Article Outline


The greatest impact of current ART regimens on the recovery of CD4 T lymphocytes occurs within the first 2 years. The degree of immunodeficiency before the initiation of ART and age are significant predictors of the subsequent recovery of CD4 T lymphocytes. This finding suggests that ART should be commenced before severe immunological damage to ensure immune restoration to normal levels.

Back to Top | Article Outline


The authors would like to thank the practitioners at the Holdsworth House General Practice and Taylor Square Private Clinic for their contribution to this study.

Back to Top | Article Outline


1. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373: 123–126.

2. Staszewski S, Miller V, Sabin C. et al. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS 1999, 13: 951–956.

3. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 1998, 351: 723–724.

4. Autran B, Carcelain G, Li T. et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277: 112–116.

5. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996, 173: 321–329.

6. Koot M, Keet IP, Vos AH. et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993, 118: 681–688.

7. Lafeuillade A, Chollet L, Hittinger G, Profizi N, Costes O, Poggi C. Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of < 200 copies/mL. J Infect Dis 1998, 177: 235–238.

8. Zhang L, Ramratnam B, Tenner-Racz K. et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999, 340: 1605–1613.

9. Renaud M, Katlama C, Mallet A. et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. AIDS 1999, 13: 669–676.

10. Cohen Stuart JW, Slieker WA, Rijkers GT. et al. Early recovery of CD4+ T lymphocytes in children on highly active antiretroviral therapy. Dutch study group for children with HIV infections. AIDS 1998, 12: 2155–2159.

11. Roederer M, Dubs JG, Anderson MT, Raju PA, Herzenberg LA. CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest 1995, 95: 2061–2066.

12. Notermans DW, Pakker NG, Hamann D. et al. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults. J Infect Dis 1999, 180: 1050–1056.

13. Arno A, Ruiz L, Juan M. et al. Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 years. AIDS 1998, 12: 697–704.

14. Connors M, Kovacs JA, Krevat S. et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997, 3: 533–540.

15. Gray CM, Schapiro JM, Winters MA, Merigan TC. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience. AIDS Res Hum Retroviruses 1998, 14: 561–569.

16. Plana M, Garcia F, Gallart T, Miro JM, Gatell JM. Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology Study Group of Spanish EARTH-1 Study. Lancet 1998, 352: 1194–1195.

17. US Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at URL:; 2001.

18. Furrer H, Egger M, Opravil M. et al. Discontinuation of primary prophylaxis againstPneumocystis cariniipneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med 1999, 340: 1301–1306.

19. Pakker NG, Roos MT, van Leeuwen R. et al. Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. J Acquir Immune Defic Syndr 1997, 16: 318–326.

20. Zhang L, Lewin SR, Markowitz M. et al. Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. J Exp Med 1999, 190: 725–732.

21. Douek DC, McFarland RD, Keiser PH. et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998, 396: 690–695.

22. Bucy RP, Hockett RD, Derdeyn CA. et al. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 1999, 103: 1391–1398.

23. Walker RE, Carter CS, Muul L. et al. Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration in HIV-infected adults. Nat Med 1998, 4: 852–856.

Cited By:

This article has been cited 81 time(s).

Immunological Reviews
Immune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs
Wilson, EMP; Sereti, I
Immunological Reviews, 254(): 343-354.
AIDS Research and Human Retroviruses
Long-term immunologic outcome in HAART-experienced subjects receiving lopinavir/ritonavir
Bongiovanni, M; Bini, T; Casana, M; Cicconi, P; Tordato, F; Monforte, AD
AIDS Research and Human Retroviruses, 22(): 1099-1105.

Clinical Infectious Diseases
Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment
Landay, A; da Silva, BA; King, MS; Albrecht, M; Benson, C; Eron, J; Glesby, M; Gulick, R; Hicks, C; Kessler, H; Murphy, R; Thompson, M; White, AC; Wolfe, P; McMillan, FI; Hanna, GJ
Clinical Infectious Diseases, 44(5): 749-754.
AIDS Research and Human Retroviruses
Immunological Recovery and Metabolic Disorders in Severe Immunodeficiency HIV Type 1-Infected Children on Highly Active Antiretroviral Therapy
Resino, S; Micheloud, D; Larru, B; Bellon, JM; Leon, JA; Resino, R; De Jose, MI; Gutierrez, MDG; Mellado, MJ; Guillen, S; Ramos, JT; Munoz-Fernandez, MA
AIDS Research and Human Retroviruses, 24(): 1477-1484.
Clinical Infectious Diseases
Nadir CD4 T Cell Count as Predictor and High CD4 T Cell Intrinsic Apoptosis as Final Mechanism of Poor CD4 T Cell Recovery in Virologically Suppressed HIV-Infected Patients: Clinical Implications
Negredo, E; Massanella, M; Puig, J; Perez-Alvarez, N; Gallego-Escuredo, JM; Villarroya, J; Villarroya, F; Molto, J; Santos, JR; Clotet, B; Blanco, J
Clinical Infectious Diseases, 50(9): 1300-1308.
Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy
Hunt, PW; Deeks, SG; Rodriguez, B; Valdez, H; Shade, SB; Abrams, DI; Kitahata, MM; Krone, M; Neilands, TB; Brand, RJ; Lederman, MM; Martin, JN
AIDS, 17(): 1907-1915.
Journal of Clinical Investigation
Growth hormone enhances thymic function in HIV-1-infected adults
Napolitano, LA; Schmidt, D; Gotway, MB; Ameli, N; Filbert, EL; Ng, MM; Clor, JL; Epling, L; Sinclair, E; Baum, PD; Li, K; Killian, ML; Bacchetti, P; McCune, JM
Journal of Clinical Investigation, 118(3): 1085-1098.
Antiviral Therapy
Predicting the magnitude of short-term CD4(+) T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy
Castagna, A; Galli, L; Torti, C; Monforte, AD; Mussini, C; Antinori, A; Cozzi-Lepri, A; Ladisa, N; De Luca, A; Seminari, E; Gianotti, N; Lazzarin, A
Antiviral Therapy, 15(2): 165-175.
Evaluation of a 6-Year Highly Active Antiretroviral Therapy in Chinese HIV-1-Infected Patients
Zhou, HY; Zheng, YH; He, Y; Chen, Z; Liu, M; Yin, W; Liu, C
Intervirology, 53(4): 240-246.
HIV Clinical Trials
Predictors of long-term immunological outcome in rebounding patients on protease inhibitor-based HAART after initial successful virologic suppression: Implications for timing to switch
Tomasoni, LR; Patroni, A; Torti, C; Paraninfo, G; Gargiulo, F; Quiros-Roldan, E; Uccelli, MC; Airo, P; Tinelli, C; Carosi, G; Castelli, F
HIV Clinical Trials, 4(5): 311-323.

International Journal of Std & AIDS
Five-year immunological outcome of highly active antiretroviral treatment in a clinical setting: results from a single HIV treatment centre
Schrooten, W; Florence, E; Dreezen, C; Van Esbroeck, M; Fransen, K; Alonso, A; Desmet, P; Colebunders, R; Kestens, L; De Roo, A
International Journal of Std & AIDS, 15(8): 523-528.

Journal of Infectious Diseases
Determinants of CD4(+) T cell recovery during suppressive antiretroviral therapy: Association of immune activation, T cell maturation markers, and cellular HIV-1 DNA
Goicoechea, M; Smith, DM; Liu, L; May, S; Tenorio, AR; Ignacio, CC; Landay, A; Haubrich, R
Journal of Infectious Diseases, 194(1): 29-37.

Clinical Immunology
Low CD4 T-cell counts despite low levels of circulating HIV: Insights from the comparison of HIV-1 infected patients with a discordant response to antiretroviral therapy to patients with untreated advanced HIV-2 disease
Albuquerque, AS; Foxall, RB; Cortesao, CS; Soares, RS; Doroana, M; Ribeiro, A; Lucas, M; Antunes, F; Victorino, RMM; Sousa, AE
Clinical Immunology, 125(1): 67-75.
Journal of Postgraduate Medicine
Increase in CD4 cell counts between 2 and 3.5 years after initiation of antiretroviral therapy and determinants of CD4 progression in India
Rajasekaran, S; Jeyaseelan, L; Raja, K; Vijila, S; Krithigaipriya, KA; Kuralmozhi, R
Journal of Postgraduate Medicine, 55(4): 261-266.
Enfermedades Infecciosas Y Microbiologia Clinica
Clinical and epidemiological study of a series of HIV-infected patients over 50 years old
Anton, E; Sala, M; Mallolas, J; Navarro, G; Cervantes, M; Gatell, JM; Segura, F
Enfermedades Infecciosas Y Microbiologia Clinica, 23(3): 145-148.

International Review of Psychiatry
Co-factors in HIV neurobehavioural disturbances: Substance abuse, hepatitis C and aging
Gonzalez, R; Cherner, M
International Review of Psychiatry, 20(1): 49-60.
AIDS Research and Human Retroviruses
Evolution of CD4(+) T Cell Count in HIV-1-Infected Adults Receiving Antiretroviral Therapy with Sustained Long-Term Virological Suppression
Byakwaga, H; Murray, JM; Petoumenos, K; Kelleher, AD; Law, MG; Boyd, MA; Emery, S; Mallon, PW; Cooper, DA
AIDS Research and Human Retroviruses, 25(6): 569-576.
Proceedings of the Royal Society B-Biological Sciences
The role of mutation accumulation in HIV progression
Galvani, AP
Proceedings of the Royal Society B-Biological Sciences, 272(): 1851-1858.
Journal of Infectious Diseases
Low CD4(+) T cell nadir is an independent predictor of lower HIV specific immune responses in chronically HIV-1-infected subjects receiving highly active antiretroviral therapy
Siddique, MA; Hartman, KE; Dragileva, E; Dondero, M; Gebretsadik, T; Shintani, A; Peiperl, L; Valentine, F; Kalams, SA
Journal of Infectious Diseases, 194(5): 661-665.

T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART
Marziali, M; De Santis, W; Carello, R; Leti, W; Esposito, A; Isgro, A; Fimiani, C; Sirianni, MC; Mezzaroma, I; Aiuti, F
AIDS, 20(): 2033-2041.

AIDS Research and Human Retroviruses
Long-term observation of adolescents initiating HAART therapy: Three-year follow-up
Flynn, PM; Rudy, BJ; Lindsey, JC; Douglas, SD; Lathey, J; Spector, SA; Martinez, J; Silio, M; Belzer, M; Friedman, L; D'Angelo, L; Smith, E; Hodge, J; Hughes, MD
AIDS Research and Human Retroviruses, 23(): 1208-1214.
Journal of Infection
Negative influence of age on CD4(+) cell recovery after highly active antiretroviral therapy in naive HIV-1-infected patients with severe immunodeficiency
Micheloud, D; Berenguer, J; Bellon, JMA; Miralles, P; Cosin, J; de Quiros, JCLB; Conde, MS; Munoz-Fernandez, MA; Resino, S
Journal of Infection, 56(2): 130-136.
Clinical Infectious Diseases
The Absence of CD4(+) T Cell Count Recovery Despite Receipt of Virologically Suppressive Highly Active Antiretroviral Therapy: Clinical Risk, Immunological Gaps, and Therapeutic Options
Gazzola, L; Tincati, C; Bellistri, GM; Monforte, AD; Marchetti, G
Clinical Infectious Diseases, 48(3): 328-337.
Clinical Infectious Diseases
Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up
Resino, S; Resino, R; Micheloud, D; Gutierrez, DG; Leon, JA; Ramos, JT; Ciria, L; de Jose, I; Mellado, J; Munoz-Fernandez, A
Clinical Infectious Diseases, 42(6): 862-869.

Lancet Infectious Diseases
Immunological recovery and antiretroviral therapy in HIV-1 infection
Battegay, M; Nuesch, R; Hirschel, B; Kaufmann, GR
Lancet Infectious Diseases, 6(5): 280-287.

Archives of Internal Medicine
Older age and the response to and tolerability of antiretroviral therapy
Silverberg, MJ; Leyden, W; Horberg, MA; DeLorenze, GN; Klein, D; Quesenberry, CP
Archives of Internal Medicine, 167(7): 684-691.

HIV Medicine
Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently < 500 copies/mL during treatment with antiretroviral drugs
Le Moing, V; Thiebaut, R; Chene, G; Sobel, A; Massip, P; Collin, F; Meyohas, MC; Al Kaied, F; Leport, C; Raffi, F
HIV Medicine, 8(3): 156-163.

Jaids-Journal of Acquired Immune Deficiency Syndromes
Antiretroviral treatment strategies and immune reconstitution in treatment-naive HIV-infected patients with advanced disease
Soria, A; Lazzarin, A
Jaids-Journal of Acquired Immune Deficiency Syndromes, 46(): S19-S30.

HIV Medicine
Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy
Byakwaga, H; Zhou, J; Petoumenos, K; Law, MG; Boyd, MA; Emery, S; Cooper, DA; Mallon, PW
HIV Medicine, 10(3): 143-151.
Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV paediatric study
Walker, AS; Doerholt, K; Sharland, M; Gibb, DM
AIDS, 18(): 1915-1924.

Journal of Infectious Diseases
Absolute count and percentage of CD4(+) lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy
Hulgan, T; Shepherd, BE; Raffanti, SP; Fusco, JS; Beckerman, R; Barkanic, G; Sterling, TR
Journal of Infectious Diseases, 195(3): 425-431.

Psychologie & Neuropsychiatrie Du Vieillissement
Dementia complex due to HIV disease and aging
Moulignier, A
Psychologie & Neuropsychiatrie Du Vieillissement, 5(3): 193-207.
Clinical Infectious Diseases
The effect of highly active antiretroviral therapy on dermatologic disease in a longitudinal study of HIV type 1-infected women
Maurer, T; Rodrigues, LKE; Ameli, N; Phanuphak, N; Gange, SJ; DeHovitz, J; French, AL; Glesby, M; Jordan, C; Khalsa, A; Hessol, NA
Clinical Infectious Diseases, 38(4): 579-584.

Journal of Infectious Diseases
Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy
Smith, CJ; Sabin, CA; Youle, MS; Kinloch-de Loes, S; Lampe, FC; Madge, S; Cropley, I; Johnson, MA; Phillips, AN
Journal of Infectious Diseases, 190(): 1860-1868.

Journal of Infectious Diseases
CD4(+) T cell recovery beyond the first year of complete suppression of viral replication during highly active antiretroviral therapy is not influenced by CD8(+) T cell activation
Benito, JM; Lopez, M; Lozano, S; Ballesteros, C; Capa, L; Martinez, P; Gonzalez- Lahoz, J; Soriano, V
Journal of Infectious Diseases, 192(): 2142-2146.

Clinical Infectious Diseases
Immune reconstitution in HIV-infected patients
Hirsch, HH; Kaufmann, G; Sendi, P; Battegay, M
Clinical Infectious Diseases, 38(8): 1159-1166.

HIV Medicine
CD4 count and viral load time-courses in patients treated with highly active antiretroviral therapy and association with the CDC staging system
Collazos, J; Knobel, H; Casado, JL
HIV Medicine, 7(8): 504-513.

Clinical Immunology
Intensification of a suppressive HAART regimen increases CD4 counts and decreases CD8+T-cell activation
Klber, MA; Saenz, MO; Tanner, TJ; Arheart, KL; Pahwa, S; Liu, FL
Clinical Immunology, 126(3): 315-321.
Expert Review of Anti-Infective Therapy
Trends in the European HIV/AIDS epidemic: a perspective from Italy
Madeddu, G; Rezza, G; Mura, MS
Expert Review of Anti-Infective Therapy, 7(1): 25-36.
HIV Medicine
Criteria for initiating highly active antiretroviral therapy and short-term immune response among HIV-1-infected patients in Cote d'Ivoire
Diabate, S; Alary, M
HIV Medicine, 10(): 640-646.
Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings
Cherner, M; Ellis, R; Lazzaretto, D; Young, C; Mindt, MR; Atkinson, JH; Grant, I; Heaton, RK
AIDS, 18(): S27-S34.

HIV Medicine
Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count >= 300 cells/mu L who were assigned to 7.5 MIU interleukin-2
Fox, Z; Antunes, F; Davey, R; Gazzard, B; Klimas, N; Labriola, A; Losso, M; Neaton, JD; Phillips, AN; Ruxrungtham, K; Staszewski, S; Weiss, L; Lundgren, JD; Abrams, DI; Cooper, DA; Abrams, DI; Cooper, DA; Darbyshire, JH; Duncan, WR; Emery, S; Lane, HC; Lehrman, S; Lundgren, JD; Neaton, JD; Aguilar, L; Angel, EB; Aquilia, S; Belloso, W; Benetucci, J; Bittar, V; Cahn, P; Casiro, A; Contarelli, J; Corral, J; Daciuk, L; David, D; Ferrari, I; Fridman, D; Galache, V; Guaragna, G; Ivalo, S; Laplume, H; Lanusse, I; Lasala, MB; Lattes, R; Lasovsky, J; Lopardo, G; Losso, M; Lourtau, L; Lupo, S; Maranzana, A; Marson, C; Massera, L; Sanchez, MD; Somenzini, C; Tocci, M; Algar, S; Anderson, J; Baker, D; Blavius, K; Bloch, M; Boyle, M; Bradford, D; Britton, P; Carrall, L; Carr, A; Chuah, J; Curry, M; D'Arcy-Evans, C; Dobson, P; Doong, N; Egan, C; Ferguson, W; Finlayson, R; French, M; Frater, A; Gold, J; Habel, P; Haig, K; Holland, R; Hyland, N; Hoy, J; Hudson, J; James, R; Leung, J; Lowe, K; MacRae, K; McMurchie, M; Medland, N; Miller, S; Murray, J; Newman, R; Orth, D; Patching, J; Primrose, R; Ree, H; Richardson, R; Rogers, G; Roney, J; Roth, N; Sarangapany, J; Shaw, D; Silberberg, C; Skett, J; Williams, L; Soo, TM; Sowden, D; Street, A; Vale, R; Villella, C; Walker, A; Watson, A; Wendt, N; Wood, H; Youds, D; Aichelburg, A; Rieger, A; Vetter, N; Clumeck, N; De Wit, S; Kabeya, K; O'Doherty, E; Amorim, CD; Basso, CR; Lewi, DS; Pereira, LC; da Silva, M; Souza, TNL; Angel, J; Bouchard, PR; Clark, F; Cohen, J; Dambreville, M; Ellis, M; Fiset, S; Foster, A; Fraser, C; Gagnon, S; Gilmour, J; Guenette, R; Haldane, H; Hawley-Foss, N; Hyndman, S; Johnston, L; Jubinville, N; Juneau, F; Kelleher, L; LaPointe, L; Latendre-Paquette, J; Lindemulder, A; Mashinter, L; Lefebvre, E; McFarland, N; Morisseau, C; O'Neill, R; Piche, A; Ralph, E; Rouleau, D; Routy, JP; Sandre, R; Schmidt, S; Shafran, S; Smaill, F; Stromberg, D; Trepanier, JM; Trottier, S; Veal, S; Walmsley, S; Weiss, K; Williams, K; Young, M; Zaleschuk, B; Zarowny, D; Baadegaard, B; Black, F; Boedker, K; Gerstoft, J; Jensen, L; Mathiesen, L; Nielsen, H; Pedersen, C; Petersen, D; Aboulker, JP; Baakili, A; Bengrait, N; Bensalem, M; Berthe, H; Bloche, M; Bazin, C; Boue, F; Bouvet, E; Brancon, C; Capitant, C; Ceppi, C; Cheneau, C; Coutellier, A; Chennebault, JM; Coquet, F; De Truchis, P; Delavalle, AM; Frixon-Marin, V; Gastaut, JA; Delfraissy, F; Eliaszeicz, M; Gallais, H; Gataut, JA; Gilquin, J; Gonzalez-Canali, G; Gaudebout, C; Goujard, C; Hoen, B; Honore, P; Jarousse, B; Lang, JM; Lefebvre, B; Levy, Y; Loison, J; Maignan, A; Meynard, JL; Michon, C; Mole, M; Marsal, L; Matheron, S; Mortier, E; Oksenhendler, E; Poirier, S; Picard-Dahan, C; Ravaux, I; Raffi, F; Raguin, G; Reynes, J; Rozenbaum, W; Salmon, D; Simon, A; Spiridon, G; Viard, JP; Vidal, M; Weiss, L; Zucman, D; Bergmann, F; Brockmeyer, N; Faetkenheuer, G; Fenske, S; Gey, D; Goebel, FD; Goetsch, M; Hartmann, M; Klinker, H; Kremer, G; Mantzsch, K; Mauss, S; Rockstroh, J; Rotty, J; Rund, E; Schneider, K; Schuermann, D; Staszweski, S; Tilmann, K; Vogel, M; Bentwich, Z; Drora, G; Kedem, E; Lang, R; Levi, I; Maayan, S; Magen, E; Mamorsky, M; Pilpul, A; Pollack, S; Sthoeger, Z; Vered, H; Yust, I; Lyons, F; Mulcahy, F; Rochford, A; Auiti, F; Angarano, G; Bertelli, D; Bini, T; Bruno, R; Cadeo, GP; Carosi, G; Monforte, AD; Del Giacco, S; Di Pietro, M; Esposito, R; Filice, G; Gavazzeni, G; Guaraldi, G; Indiveri, F; Lazzarin, A; Mazzotta, F; Minolli, L; Montroni, M; Moroni, M; Nozza, S; Pastor, G; Poli, G; Raise, E; Romagnani, S; Rusconi, V; Sacchi, P; Suter, F; Tambussi, G; Tirelli, U; Fraser, H; Iwamoto, A; Kikuchi, Y; Mori, M; Nakamura, T; Odawara, T; Oka, S; Shirasaka, T; Takano, M; To, J; Ueta, C; El Filali, K; Erradey, I; Himmich, H; Blok, W; Borleffs, J; Bravenboer, B; Bronveld, W; Claessen, F; Duurvoort, M; Ferwerda, J; Frissen, P; Hulshoff, N; Juttman, J; Kauffmann, R; Koopmans, P; Kroon, F; Lowe, S; Leemhuis, M; Meenhorst, P; de Boer, LP; Reiss, P; Reinders-Folmer, S; Richter, C; Santegoets, R; Schoemaker, M; Schrey, G; Sprenger, H; Ten Veen, J; Tessalaar, J; van der Ende, M; van der Vall, H; van Eeden, A; van Leeuwen, R; Vermeulen, J; ten Kate, RW; van Boxtel, R; van Eden, A; van de Ven, B; van der Meulen, P; ten Napei, C; Vriesendrop, R; Bruun, J; Bakowska, E; Beniowski, M; Boron-Kaczmarska, A; Gasiorowski, J; Gxadysz, A; Horban, A; Knysz, B; Mularska, E; Pynka, M; Szymczak, A; Aldir, I; Antunes, F; Doroana, M; Duque, L; Mansinho, K; Pinto, I; Valadas, E; Vera, J; Foo, E; Panchalingham, A; Lim, PL; Paton, N; Peperstraete, B; Quek, A; Alcazar-Caballero, R; Arrizabalaga, J; Bouza, E; Cepeda, C; de Barron, X; Jimenez, MC; Clotet, B; Cortes, L; Domingo, P; Fernandez, P; Fernandez-Cruz, E; Fuster, M; Gatell, J; Gijon, P; Gil, I; Gonzales-Lahoz, J; Gonzalez, A; Hernandez, M; Iribarren, J; Jimenez, M; Knobel, H; Leon, A; Lopez, JC; Lozano, A; Lopez, P; Moreno, J; Munoz, R; Padilla, B; Parras, A; Pastor, A; Pedreira, J; Pristo, J; Pena, J; Roca, V; Rubio, R; de Rivera, JS; Sanz, J; Tamargo, L; Torres, R; Pehrson, PO; Sandstrom, E; Bernasconi, E; Gurtner, V; Magenta, L; Ampunpong, U; Bowonwatnuwong, C; Chanchai, P; Chetchotisakd, P; Chuenyam, T; Duncombe, C; Horsakulthai, M; Kantipong, P; Liddy, J; Phanuphak, P; Pongsurachet, V; Ruxrungtham, K; Seekaew, S; Sonjai, A; Subsri, N; Suwanagool, S; Techasathit, W; Wankoon, J; Adebiyi, A; Aldam, D; Alexander, I; Angus, B; Barber, T; Bonnington, S; Care, C; Carroll, A; Cornforth, D; Donaldson, O; Druiff, L; Easterbrook, P; Edwards, B; Ellis, C; Erradey, I; El Filali, K; Fisher, M; Fox, R; Gazzard, B; Harrison, A; Herman, S; Heald, L; Higgs, C; Himmich, H; Jendrulek, I; Johnson, M; Judges, L; Karim, F; Kinghorn, G; Laurenti, J; Lee, C; Leen, C; Legg, K; Lyons, F; Maw, R; MacConachie, A; McKernan, S; McLean, L; McMillan, A; Mguni, S; Morris, S; Mulchay, F; Mullan, D; Mullaney, S; Murphy, M; Nunn, A; Ong, E; Owen, M; Palfreeman, A; Perry, N; Peters, B; Pozniak, A; Rochford, A; Ronan, A; Skinner, C; Stroud, C; Takawira, M; Tamm, N; Thomas, R; Yee, TT; Vanthuyne, A; Wansborough-Jones, M; Weber, J; White, D; Wilkins, E; Wiselka, M; Williams, I; Waugh, M; Wotherspoon, J; Youle, M; Doyle, M; Goodwin, E; Luskin-Hawk, R; Sullivan, J; Verheggen, R; Abrams, D; Baxter, J; Besch, CL; Child, C; Cohn, D; Cooper, P; El-Sadr, W; Farrough, M; Fisher, E; Fuentes, L; Goodwin, E; Gordin, F; Graeber, C; Kelly, ME; Kostman, J; Labriola, A; Lattanzi, K; MacArthur, R; Makohon, L; Markowitz, NP; Martinez, N; Mastro-Polak, D; Mitchell, V; Mushatt, D; Patterson, K; Perez, G; Rosmarin, C; Rouff, JR; Saldanha, J; Sampson, J; Sawyer, R; Standridge, B; Sullivan, J; Sweeton, B; Tedaldi, E; Thompson, M; Valencia, P; Verlinghieri, G; Walker, J; Watson, V; Williams, B; Armstrong, A; Banks, S; Blazes, D; Barile, A; Coelho, L; Dennis, M; Flaks, H; Gilcrest, J; Gittens, K; Hopper, S; Humphries, MJ; Spooner, K; Tamminga, CL; Vita, J; Wegner, SA; Wortmann, G; Bisby, N; Blake, W; Brown, S; Chilliade, P; Cole, T; Elliot, K; Geisler, C; Goetz, M; Gomez-Perez, E; Gordin, F; Helman, J; Klimas, N; Labriola, A; Nahass, R; LeFlore, D; Marston, B; Obregon, M; Petrolati, J; Pitrak, DL; Roland, R; Rosa, C; Rossman, B; Wirtz, SS; Schuck, S; Scretchings, T; Simon, G; Smith, M; Standridge, B; Summers, K; Werhane, MJ; Arduino, R; Bell, B; Breaux, K; Cuervo, H; Hale, C; Lewis, S; Mall, M; Mora, F; Diez, MM; Okhuysen, P; Rodriguez-Barradas, M; Schrader, SR; Healy, L; Kaszubski, C; Kolber, M; Tanner, T; Armstrong, J; Dahlke, J; Johnson, L; Kaminski, P; Rhame, F; Shoden, C; Temesgen, Z; Urbanich, M; Valenti, S; Zervos, M; Davey, R; Barrick, B; Chaitt, D; Hahn, B; Lane, C; Martell, D; McNay, L; Metcalf, J; Powers, A; Tavel, JA; Loveless, K; Martinez, N; Peterson, S; Sampson, J; Sweek, S; Abrams, D; Albrecht, H; Antoine, N; Kelly, ME; Pell, P; Belloso, W; Gatell, JM; Hoy, J; Lifson, A; Pederson, C; Rhame, F; El-Sadr, W; Borup, L; Dragsted, UB; Greve, AF; Jensen, K; Lundgren, J; Mollerup, D; Pearson, M; Phillips, A; Aboulhab, J; Angus, B; Babiker, A; Cordwell, B; Darbyshire, J; Hack, L; Hooker, M; Moraes, Y; Newberry, D; Nuwagaba-Biribonwoha, H; van Hooff, F; Denning, E; Klemme, LH; Carey, C; Chan, F; Cooper, D; Courtney-Rodgers, D; Drummond, F; Emery, S; Jacoby, S; Law, M; Stewart, M; Pett, S; Alloo, Z; Bebchuk, J; Bollenbeck, P; DuChene, AG; Fosdick, L; Harrison, M; Krum, E; Larson, G; Lifson, A; Meger, S; Neaton, J; Nelson, R; Quan, SFL; Schultz, T; Telke, S; Thackeray, L; Thompson, G; Wentworth, D; Wyman, N; Duncan, W; Ferguson, E; Fox, L; Gettinger, N; Herrera, J; Lehrman, S; Luzar, MA; Maeshiro, M; Martinez, A; Oseekey, K; Baigent, G; Capra, W; Duliege, AM; Fitzgerald, L; Kwakkelstein, M; Maral, J; O'Hara, M; Sahner, D; Weber, C; Adam-Perchec, C; Barron, N; Bell, ML; Dolan, S; Eckstrand, J; Hicks, S; McAuley, G; Beck, S; Brown, S; Rupert, A
HIV Medicine, 8(2): 112-123.

AIDS Research and Human Retroviruses
CD4 Responses in the Setting or Suboptimal Virological Responses to Antiretroviral Therapy: Features, Outcomes, and Associated Factors
Collazos, J; Asensi, V; Carton, JA
AIDS Research and Human Retroviruses, 25(7): 647-655.
Clinical Infectious Diseases
Nadir CD4(+) T cell count predicts response to subcutaneous recombinant interleukin-2
Markowitz, N; Bebchuk, JD; Abrams, DI
Clinical Infectious Diseases, 37(8): E115-E120.

Antiviral Therapy
Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection
Kaufmann, IR; Khanna, N; Weber, R; Perrin, L; Furrer, H; Cavassini, M; Ledergerber, B; Vernazza, P; Bernasconi, E; Rickenbach, M; Hirschel, B; Battegay, M
Antiviral Therapy, 9(2): 263-274.

AIDS Research and Human Retroviruses
Nadir CD4 Cell Count Predicts Neurocognitive Impairment in HIV-Infected Patients
Munoz-Moreno, JA; Fumaz, CR; Ferrer, MJ; Prats, A; Negredo, E; Garolera, M; Perez-Alvarez, N; Molto, J; Gomez, G; Clotet, B
AIDS Research and Human Retroviruses, 24(): 1301-1307.
Journal of Infectious Diseases
T cell activation is associated with lower CD4(+) T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy
Hunt, PW; Martin, JN; Sinclair, E; Bredt, B; Hagos, E; Lampiris, H; Deeks, SG
Journal of Infectious Diseases, 187(): 1534-1543.

Studies on the potential use of CD38 expression as a marker for the efficacy of anti-retroviral therapy in HIV-1-infected patients in Thailand
Onlamoon, N; Tabprasit, S; Suwanagool, S; Louisirirotchanakul, S; Ansari, AA; Pattanapanyasat, K
Virology, 341(2): 238-247.
Journal of Infectious Diseases
Immunological and virological failure after antiretroviral therapy is associated with enhanced peripheral and thymic pathogenicity
Solomon, A; Cameron, PU; Bailey, M; Dunne, AL; Crowe, SM; Hoy, JF; Lewin, SR
Journal of Infectious Diseases, 187(): 1915-1923.

Scandinavian Journal of Infectious Diseases
Prognostic value of changes in CD4 count and HIV RNA during the first six months on highly active antiretroviral therapy in chronic human immunodeficiency virus infection
Ormaasen, V; Bruun, JN; Sandvik, L; Holberg-Petersen, M; Gaarder, PI
Scandinavian Journal of Infectious Diseases, 35(): 383-388.
Current HIV Research
Inpatient care of the HIV infected patient in the highly active antiretroviral therapy (HAART) era
Pulvirenti, JJ
Current HIV Research, 3(2): 133-145.

How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control
Lawn, SD; Bekker, LG; Wood, R
AIDS, 19(): 1113-1124.

Diagnostic virologic accuracy of CD4 cell count increase for response after initiating highly active antiretroviral therapy
Bisson, GP; Gross, R; Strom, JB; Rollins, C; Bellamy, S; Weinstein, R; Friedmand, H; Dickinson, D; Frank, I; Strom, BL; Gaolathe, T; Ndwapi, N
AIDS, 20(): 1613-1619.

Bmc Infectious Diseases
CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa
Lawn, SD; Myer, L; Bekker, LG; Wood, R
Bmc Infectious Diseases, 6(): -.
AIDS Reviews
Failure to reconstitute CD4+T-cells despite suppression of HIV replication under HAART
Aiuti, F; Mezzaroma, L
AIDS Reviews, 8(2): 88-97.

Bmc Infectious Diseases
Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more
Nogueras, M; Navarro, G; Anton, E; Sala, M; Cervantes, M; Amengual, M; Segura, F
Bmc Infectious Diseases, 6(): -.
ARTN 159
American Journal of Tropical Medicine and Hygiene
Modeling CD4+Cell Count Increase Over a Six-Year Period in HIV-1-Infected Patients on Highly Active Antiretroviral Therapy in Senegal
De Beaudrap, P; Etard, JF; Diouf, A; Ndiaye, I; Gueye, NF; Gueye, PM; Sow, PS; Mboup, S; Ndoye, I; Ecochard, R; Delaporte, E
American Journal of Tropical Medicine and Hygiene, 80(6): 1047-1053.

Journal of Medical Virology
Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapy
Chiappini, E; Galli, L; Zazzi, M; de Martino, M
Journal of Medical Virology, 70(4): 506-512.
Clinical Infectious Diseases
Characteristics, determinants, and clinical relevance of CD4 T cell recovery to < 500 cells/mu L in HIV type 1-infected individuals receiving potent antiretroviral therapy
Kaufmann, GR; Furrer, H; Ledergerber, B; Perrin, L; Opravil, M; Vernazza, P; Cavassini, M; Bernasconi, E; Rickenbach, M; Hirschel, B; Battegay, M
Clinical Infectious Diseases, 41(3): 361-372.

International Journal of Infectious Diseases
Predictors of CD4+ cell count response and of adverse outcome among HIV-infected patients receiving highly active antiretroviral therapy in a public hospital in Peru
de Castilla, DL; Verdonck, K; Otero, L; Iglesias, D; Echevarria, J; Lut, L; Gotuzzo, E; Seas, C
International Journal of Infectious Diseases, 12(3): 325-331.
Clinical Infectious Diseases
CD4(+) T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy
Khanna, N; Opravil, M; Furrer, H; Cavassini, M; Vernazza, P; Bernasconi, E; Weber, R; Hirschel, B; Battegay, M; Kaufmann, GR
Clinical Infectious Diseases, 47(8): 1093-1101.
Long-term changes in circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretroviral therapy
Smith, K; Aga, E; Bosch, RJ; Valdez, H; Connick, E; Landay, A; Kuritzkes, D; Gross, BH; Francis, IR; McCune, JM; Kessler, H; Lederman, M
AIDS, 18(): 1953-1956.

Clinical Infectious Diseases
The modern ART of HIV infection management: Towards a tailored approach to maximize CD4 T cell reconstitution
Sasson, SC; Kelleher, AD; Cooper, DA
Clinical Infectious Diseases, 41(3): 373-375.

Fems Immunology and Medical Microbiology
Changes in T-cell subpopulations during four years of suppression of HIV-1 replication in patients with advanced disease
Lepej, SZ; Begovac, J; Vince, A
Fems Immunology and Medical Microbiology, 46(3): 351-359.
Bmc Infectious Diseases
Impact of long-term viral suppression in CD4+ recovery of HIV-children on Highly Active Antiretroviral therapy
Resino, S; Resino, R; Leon, JA; Bellon, JM; Martin-Fontelos, P; Ramos, JT; Gurbindo-Gutierrez, D; de Jose, MI; Ciria, L; Munoz-Fernandez, MA
Bmc Infectious Diseases, 6(): -.
International Journal of Infectious Diseases
Older HIV-infected patients-an underestimated population in northern Greece: epidemiology, risk of disease progression and death
Metallidis, S; Tsachouridou, O; Skoura, L; Zebekakis, P; Chrysanthidis, T; Pilalas, D; Bakaimi, I; Kollaras, P; Germanidis, G; Tsiara, A; Galanos, A; Malisiovas, N; Nikolaidis, P
International Journal of Infectious Diseases, 17(): E883-E891.
Five-year follow-up of a cohort of profoundly immunosuppressed patients discontinuing therapy for cytomegalovirus retinitis
Polis, MA; Sklar, PA; Agyemang, AF; Monastra, R; Kress, DR; Metcalf, JA; Robinson, MR; Masur, H
AIDS, 18(3): 567-569.

PDF (164)
Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies
Nash, D; Katyal, M; Brinkhof, MW; Keiser, O; May, M; Hughes, R; Dabis, F; Wood, R; Sprinz, E; Schechter, M; Egger, M; for the ART-LINC Collaboration of IeDEA,
AIDS, 22(17): 2291-2302.
PDF (278) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Pretreatment Factors Associated With 3-Year (144-Week) Virologic and Immunologic Responses to Potent Antiretroviral Therapy
Bosch, RJ; Bennett, K; Collier, AC; Zackin, R; Benson, CA; for the AIDS Clinical Trials Group Protocol A5001 Team,
JAIDS Journal of Acquired Immune Deficiency Syndromes, 44(3): 268-277.
PDF (155) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Treating Advanced HIV Infection
Boffito, M; Bonora, S; Sinicco, A; Raiteri, R; Milia, MG; Khoo, SH; Hoggard, PG; Back, DJ; Perri, GD
JAIDS Journal of Acquired Immune Deficiency Syndromes, 34(3): 344-345.

PDF (1584)
JAIDS Journal of Acquired Immune Deficiency Syndromes
Differences in Factors Associated With Initial Growth, CD4, and Viral Load Responses to ART in HIV-Infected Children in Kampala, Uganda, and the United Kingdom/Ireland
Kekitiinwa, A; Lee, KJ; Walker, AS; Maganda, A; Doerholt, K; Kitaka, SB; Asiimwe, A; Judd, A; Musoke, P; Gibb, DM; on behalf of the Collaborative HIV Paediatric Study (CHIPS) Steering Committee and the Mulago Cohort Team,
JAIDS Journal of Acquired Immune Deficiency Syndromes, 49(4): 384-392.
PDF (264) | CrossRef
The Pediatric Infectious Disease Journal
Low Immunologic Response to Highly Active Antiretroviral Therapy in Naive Vertically Human Immunodeficiency Virus Type 1-Infected Children With Severe Immunodeficiency
Léon, JA; Ramos, JT; Ciria, L; Muñoz-Fernández, MÁ; Resino, S; Alvaro-Meca, A; de José, MI; Martin-Fontelos, P; Gutiérrez, MD
The Pediatric Infectious Disease Journal, 25(4): 365-368.
PDF (914) | CrossRef
CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART
Massanella, M; Negredo, E; Pérez-Álvarez, N; Puig, J; Ruiz-Hernández, R; Bofill, M; Clotet, B; Blanco, J
AIDS, 24(7): 959-968.
PDF (343) | CrossRef
The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy
Carroll, A; Prinz, B; Youle, M; Johnson, MA; Phillips, AN; Smith, CJ; Sabin, CA; Lampe, FC; Kinloch-de-Loes, S; Gumley, H
AIDS, 17(7): 963-969.

PDF (108)
Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia
Mocroft, A; Phillips, AN; Ledergerber, B; Katlama, C; Chiesi, A; Goebel, F; Knysz, B; Antunes, F; Reiss, P; Lundgren, JD; for the EuroSIDA StudyGroup,
AIDS, 20(8): 1141-1150.
PDF (256) | CrossRef
CD38+CD8+ T-cells negatively correlate with CD4 central memory cells in virally suppressed HIV-1-infected individuals
Kolber, MA
AIDS, 22(15): 1937-1941.
PDF (105) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Long-Term Patterns in CD4 Response Are Determined by an Interaction Between Baseline CD4 Cell Count, Viral Load, and Time: The Asia Pacific HIV Observational Database (APHOD)
Egger, S; Petoumenos, K; Kamarulzaman, A; Hoy, J; Sungkanuparph, S; Chuah, J; Falster, K; Zhou, J; Law, MG; on behalf of the Asia Pacific HIV Observational Database (APHOD),
JAIDS Journal of Acquired Immune Deficiency Syndromes, 50(5): 513-520.
PDF (273) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
CD4 Cell Counts of 800 Cells/mm3 or Greater After 7 Years of Highly Active Antiretroviral Therapy Are Feasible in Most Patients Starting With 350 Cells/mm3 or Greater
Gras, L; Kesselring, AM; Griffin, JT; van Sighem, A; Fraser, C; Ghani, AC; Miedema, F; Reiss, P; Lange, JM; de Wolf, F; on Behalf of the ATHENA, Netherlands National Observational Cohort Study,
JAIDS Journal of Acquired Immune Deficiency Syndromes, 45(2): 183-192.
PDF (507) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Poor Initial CD4+ Recovery With Antiretroviral Therapy Prolongs Immune Depletion and Increases Risk for AIDS and Non-AIDS Diseases
Baker, JV; Peng, G; Rapkin, J; Krason, D; Reilly, C; Cavert, WP; Abrams, DI; MacArthur, RD; Henry, K; Neaton, JD; for the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA),
JAIDS Journal of Acquired Immune Deficiency Syndromes, 48(5): 541-546.
PDF (936) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Changes in the Slope of the CD4 Cell Count Increase After Initiation of Potent Antiretroviral Treatment
Bosch, RJ; Wang, R; Vaida, F; Lederman, MM; Albrecht, MA; for the AIDS Clinical Trial Group 364 Study Team,
JAIDS Journal of Acquired Immune Deficiency Syndromes, 43(4): 433-435.
PDF (97) | CrossRef
The Pediatric Infectious Disease Journal
Pattern and Predictors of Immunologic Recovery in Human Immunodeficiency Virus-Infected Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor-Based Highly Active Antiretroviral Therapy
Puthanakit, T; Kerr, SJ; Ananworanich, J; Bunupuradah, T; Boonrak, P; Sirisanthana, V
The Pediatric Infectious Disease Journal, 28(6): 488-492.
PDF (209) | CrossRef
Back to Top | Article Outline

Antiretroviral therapy; CD4 and CD8 cells; HIV; immune reconstitution; T lymphocytes

© 2002 Lippincott Williams & Wilkins, Inc.


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.